CVE-2019-11212

TIBCO MDM Exposes Cross-Site Scripting Vulnerabilities

Description

The MDM server component of TIBCO Software Inc's TIBCO MDM contains multiple vulnerabilities that theoretically allow an authenticated user with specific roles to perform cross-site scripting (XSS) attacks. This issue affects TIBCO Software Inc.'s TIBCO MDM version 9.0.1 and prior versions; version 9.1.0.

Remediation

Solution:

  • TIBCO has released updated versions of the affected systems which address these issues: TIBCO MDM versions 9.0.1 and below update to version 9.0.2 or higher. TIBCO MDM version 9.1.0 update to version 9.1.2 or higher.

Category

6.3
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.24%
Vendor Advisory tibco.com Vendor Advisory tibco.com
Affected: TIBCO Software Inc. TIBCO MDM
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2019-11212?
CVE-2019-11212 has been scored as a medium severity vulnerability.
How to fix CVE-2019-11212?
To fix CVE-2019-11212: TIBCO has released updated versions of the affected systems which address these issues: TIBCO MDM versions 9.0.1 and below update to version 9.0.2 or higher. TIBCO MDM version 9.1.0 update to version 9.1.2 or higher.
Is CVE-2019-11212 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2019-11212 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2019-11212?
CVE-2019-11212 affects TIBCO Software Inc. TIBCO MDM.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.